Basit öğe kaydını göster

Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation

dc.contributor.authorShestakova, Marina V.
dc.contributor.authorSatman, Ilhan
dc.contributor.authorTrubitsyna, Natalya P.
dc.contributor.authorPiletic, Milivoj
dc.contributor.authorLeiter, Lawrence A.
dc.date.accessioned2021-03-04T08:45:33Z
dc.date.available2021-03-04T08:45:33Z
dc.identifier.citationLeiter L. A. , Shestakova M. V. , Trubitsyna N. P. , Piletic M., Satman I., "Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation", DIABETES RESEARCH AND CLINICAL PRACTICE, cilt.112, ss.50-56, 2016
dc.identifier.issn0168-8227
dc.identifier.othervv_1032021
dc.identifier.otherav_64e05477-80b3-4f0c-bfdf-c0ca22517802
dc.identifier.urihttp://hdl.handle.net/20.500.12627/70169
dc.identifier.urihttps://doi.org/10.1016/j.diabres.2015.11.001
dc.description.abstractAim: The 6-months titration profile of a new scored gliclazide modified release (MR) formulation (MR 60 mg) was explored in individuals with type 2 diabetes.
dc.language.isoeng
dc.subjectEndokrinoloji ve Metabolizma Hastalıkları
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectENDOKRİNOLOJİ VE METABOLİZMA
dc.titleImplementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation
dc.typeMakale
dc.relation.journalDIABETES RESEARCH AND CLINICAL PRACTICE
dc.contributor.departmentUniversity Of Toronto , ,
dc.identifier.volume112
dc.identifier.startpage50
dc.identifier.endpage56
dc.contributor.firstauthorID230121


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster